Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Announces Second Quarter Results

GlobeNewswire October 14, 2014

Neptune Announces Second Quarter Results

GlobeNewswire October 14, 2014

Acasti Announces Positive Top-Line Pharmacokinetic Results

GlobeNewswire September 30, 2014

Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C

GlobeNewswire September 29, 2014

Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston

GlobeNewswire July 24, 2014

Acasti Announces First Quarter Results

GlobeNewswire July 15, 2014

Microcap Report: Acasti Pharma (V.APO) completes trials, Perseus Mining (T.PRU) receives VAT refunds

Stockhouse Editorial July 9, 2014

Acasti Pharma (V.APO) gains 8% on completing Phase II and pharmacokinetic trials

Stockhouse Editorial July 9, 2014

Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials

GlobeNewswire July 9, 2014

Acasti Grants of Stock Options to Newly Appointed Board Members

Marketwired June 26, 2014

Acasti Reports Results of Annual and Special Meeting

GlobeNewswire June 20, 2014

Acasti Announces Resignation of Chief Financial Officer

GlobeNewswire June 16, 2014

Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer

Marketwired May 30, 2014

Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO

GlobeNewswire May 23, 2014

Acasti Announces Fourth Quarter and Fiscal Year Results

GlobeNewswire May 21, 2014

Acasti to Present at Two Scientific Forums

GlobeNewswire May 1, 2014

Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer

GlobeNewswire April 28, 2014

Neptune and Enzymotec Conclude Final Patent Infringement Settlement ad License Agreement

GlobeNewswire April 27, 2014

Neptune & Acasti Give Update on Patent Litigations With Enzymotec

GlobeNewswire April 1, 2014

Neptune Announces Pricing of US$25 Million Offering of Common Shares

GlobeNewswire February 28, 2014